Opinion|Videos|September 27, 2024
Implications of Combination Regimens for R/R MM
Rafael Fonseca, MD, discusses the role of bispecifics in relapsed/refractory multiple myeloma and the implications of incorporating them into combination regimens.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What is the potential role and implications of incorporating bispecifics into combination regimens for the treatment of R/R MM?
Advertisement
Related to this article
In a phase 2 trial, CD38-targeted immune-PET detected active multiple myeloma in some patients with no signs of disease on standard fluorodeoxyglucose PET/CT.
“If it is successful, you should be able to access this combination wherever you are,” said Natalie S. Callander, MD, of the UW Carbone Cancer Center.
Data from the phase 3 CERVINO trial support the application for etentamig as a treatment for adults with relapsed or refractory multiple myeloma.
The MagnetisMM-32 trial may support elranatamab as an important option for those whose disease has progressed following anti-CD38 therapy and lenalidomide.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves SC Amivantamab for Recurrent/Metastatic HNSCC
2
FDA Sets PDUFA Date for Rivoceranib/Camrelizumab Resubmission After Third CRL in Unresectable HCC
3
Setting Up an HDR Brachytherapy Program Amid a National Decline
4
Durvalumab Plus FLOT, ctDNA, and Biomarker Testing in Gastroesophageal Cancer
5